Neuroventi Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $752K

  • Investors
  • 8

Neuroventi General Information

Description

Developer of neurological disorder therapies designed to provide anti-aging shields for ventricular-sized brain function. The company's therapies target various molecular processes for the treatment of autism spectrum disorder and attention deficit hyperactivity disorder, along with drug discovery services for natural products, enabling medical professionals to efficiently treat and prevent brain development disorders.

Contact Information

Website
www.neuroventi.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 15, Seolleung-ro 121-gil
  • Gangnam-gu
  • Seoul, 06100
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 15, Seolleung-ro 121-gil
  • Gangnam-gu
  • Seoul, 06100
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuroventi Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 19-Mar-2024 $752K Completed Clinical Trials - General
5. Later Stage VC (Series A) 01-Jan-2020 Completed Clinical Trials - General
4. Accelerator/Incubator 01-Aug-2018 Completed Clinical Trials - General
3. Grant 01-Oct-2017 Completed Clinical Trials - General
2. Accelerator/Incubator 01-Jun-2017 $127K Completed Clinical Trials - General
1. Early Stage VC 01-Apr-2016 $127K $127K Completed Startup
To view Neuroventi’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neuroventi Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Neuroventi Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025206783-A1 Composition for preventing, alleviating, or treating emotional disturbance comprising rilmenidine Pending 28-Mar-2024
US-20240417385-A1 Compound and use thereof for treating emotional behavioral disorders Pending 08-Sep-2021
EP-4400494-A1 Novel compound and use thereof for treating emotional behavioral disorders Pending 08-Sep-2021
EP-4400494-A4 Novel compound and use thereof for treating emotional behavioral disorders Pending 08-Sep-2021
WO-2023038456-A1 Novel compound and use thereof for treating emotional behavioral disorders Inactive 08-Sep-2021 A61K31/496
To view Neuroventi’s complete patent history, request access »

Neuroventi Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neuroventi Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
HLB Investment Corporate Venture Capital Minority
Korea Investment Partners Venture Capital Minority
Medytox Venture Investment Corporate Venture Capital Minority
Seoul Biohub Accelerator/Incubator
Ministry of SMEs and Startups Government
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Neuroventi FAQs

  • When was Neuroventi founded?

    Neuroventi was founded in 2015.

  • Where is Neuroventi headquartered?

    Neuroventi is headquartered in Seoul, South Korea.

  • What is the size of Neuroventi?

    Neuroventi has 14 total employees.

  • What industry is Neuroventi in?

    Neuroventi’s primary industry is Drug Discovery.

  • Is Neuroventi a private or public company?

    Neuroventi is a Private company.

  • What is Neuroventi’s current revenue?

    The current revenue for Neuroventi is .

  • How much funding has Neuroventi raised over time?

    Neuroventi has raised $879K.

  • Who are Neuroventi’s investors?

    HLB Investment, Korea Investment Partners, Medytox Venture Investment, Seoul Biohub, and Ministry of SMEs and Startups are 5 of 8 investors who have invested in Neuroventi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process